Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Antares Pharma, Inc. (NASDAQ: ATRS).

Full DD Report for ATRS

You must become a subscriber to view this report.


Recent News from (NASDAQ: ATRS)

Myriad Genetics: When Frustration Overrides Fact
A Bloomberg article in January, 2017 explained the history of the misconceptions surrounding the role of sell-side analysts. Most investors believe the primary job function of a sell-side analyst is to research a stock and provide a buy or sell recommendation. But, there's supporting evidenc...
Source: SeekingAlpha
Date: September, 06 2018 11:48
Report: Developing Opportunities within Anthera Pharmaceuticals, NRG Energy, Antares Pharma, El Pollo Loco, Paychex, and Cinedigm - Future Expectations, Projections Moving into 2018
NEW YORK, Aug. 31, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Anthera Pharmaceuticals, Inc. (OTC:ANTH), NRG Energy, Inc. (NYSE:NRG), An...
Source: GlobeNewswire
Date: August, 31 2018 07:40
Antares Pharma to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
EWING, N.J., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Rodman & Renshaw 20 th Annual Global Investment Conference, sponsored by H. C. Wainwright & Co. LLC., ...
Source: GlobeNewswire
Date: August, 30 2018 07:00
Antares Pharma: Proven Business Model Set To Move Much Higher
Following a big move of Antares Pharma ( ATRS ) shares from about $2.00 at the beginning of 2018 to near $3.40 currently (70% gain) some investors may question the potential for further upside in the shares near term. However, near-term catalysts bode well for a continued rally through at leas...
Source: SeekingAlpha
Date: August, 20 2018 07:49
Today's Research Reports on Stocks to Watch: Antares Pharma and Adamis Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / August 17, 2018 / Biotech stocks Antares Pharma rose marginally and Adamis Pharmaceuticals was in the red on Thursday after news of Teva receiving FDA approval for its generic version of the EpiPen. RDI Initiates Coverage on: Antares Pharma, Inc. https://...
Source: ACCESSWIRE IA
Date: August, 17 2018 08:00
Antares Pharma announces FDA approval of generic EpiPen utilizing VIBEX Auto Injector
Antares Pharma (NASDAQ: ATRS ) announces that the FDA has approved Teva Pharmaceutical Industries' epinephrine auto injector drug-device combination product indicated for emergency treatment of severe allergic reactions including those that are life threatening (anaphylaxis) in adults and ...
Source: SeekingAlpha
Date: August, 17 2018 07:05
Antares Pharma Announces FDA Approval of Generic EpiPen Utilizing VIBEX Auto Injector
EWING, N.J., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) today announced that the U.S. Food and Drug Administration (FDA) has approved Teva Pharmaceutical Industries, Ltd.’s (“Teva”) epinephrine auto injector drug-devi...
Source: GlobeNewswire
Date: August, 16 2018 16:54
Today's Research Reports on Stocks to Watch: Xenetic Biosciences and Antares Pharma
NEW YORK, NY / ACCESSWIRE / August 14, 2018 / There was no news to explain the sudden jump shares of Xenetic Biosciences saw in Monday’s trading session. Shares of Antares Pharma also climbed higher despite any news. It was momentum that kept the stock going after the company announc...
Source: ACCESSWIRE IA
Date: August, 14 2018 08:00
Midday Gainers / Losers (08/13/2018)
Gainers: ABIL +50% . IDRA +23% . TKAT +21% . CHRA +18% . XBIO +17% . DBD +18% . PTIE +13% . MTEX +13% . ITUS +12% . ATRS +11% . More news on: Ability Inc., Idera Pharmaceuticals, Inc., Takung Art Co., Ltd., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 13 2018 12:53
Robbins Arroyo LLP: Antares Pharma, Inc. (ATRS) Misled Shareholders According to a Class Action
Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Antares Pharma, Inc. (NasdaqCM: ATRS) have filed a class action complaint against the company's officers and directors for alleged violations of the Securities Exchange Act of 1934 between December 21, 2016 and Oct...
Source: Business Wire
Date: August, 07 2018 16:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-073.393.173.393.161,104,211
2018-12-063.353.373.4253.30551,044,127
2018-12-053.623.413.653.391,272,868
2018-12-043.623.403.653.391,103,509
2018-12-033.673.6453.673.57786,537

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-07221,955370,16959.9605Short
2018-12-0674,392260,75528.5295Cover
2018-12-04178,526334,57953.3584Short
2018-12-0393,814266,40635.2147Short
2018-11-30147,290711,46120.7025Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ATRS.


About Antares Pharma, Inc. (NASDAQ: ATRS)

Logo for Antares Pharma, Inc. (NASDAQ: ATRS)

Not available

 

Contact Information

 

 

Current Management

  • Paul K. Wotton / President, CEO
  • Robert Apple / CFO

Current Share Structure

  • Market Cap: $391,972,465 - 05/14/2018
  • Issue and Outstanding: 156,788,986 - 03/01/2018

 


Recent Filings from (NASDAQ: ATRS)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 13 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 05 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 16 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: ATRS)

Daily Technical Chart for (NASDAQ: ATRS)


Stay tuned for daily updates and more on (NASDAQ: ATRS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ATRS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ATRS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ATRS and does not buy, sell, or trade any shares of ATRS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/